ATE403157T1 - Verwendung des bnp-art und anp-art peptiden für das festsetzen der gefahren von herzgefäss- komplikationen als folge der volumenüberlastung - Google Patents

Verwendung des bnp-art und anp-art peptiden für das festsetzen der gefahren von herzgefäss- komplikationen als folge der volumenüberlastung

Info

Publication number
ATE403157T1
ATE403157T1 AT05005356T AT05005356T ATE403157T1 AT E403157 T1 ATE403157 T1 AT E403157T1 AT 05005356 T AT05005356 T AT 05005356T AT 05005356 T AT05005356 T AT 05005356T AT E403157 T1 ATE403157 T1 AT E403157T1
Authority
AT
Austria
Prior art keywords
art
anp
bnp
hazards
determining
Prior art date
Application number
AT05005356T
Other languages
English (en)
Inventor
Georg Hess
Andrea Horsch
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35005597&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE403157(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Application granted granted Critical
Publication of ATE403157T1 publication Critical patent/ATE403157T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/58—Atrial natriuretic factor complex; Atriopeptin; Atrial natriuretic peptide [ANP]; Cardionatrin; Cardiodilatin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/57509—Corticotropin releasing factor [CRF] (Urotensin)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/575—Hormones
    • G01N2333/58—Atrial natriuretic factor complex; Atriopeptin; Atrial natriuretic peptide [ANP]; Brain natriuretic peptide [BNP, proBNP]; Cardionatrin; Cardiodilatin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G01N2800/324—Coronary artery diseases, e.g. angina pectoris, myocardial infarction
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Cardiology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
AT05005356T 2004-03-15 2005-03-11 Verwendung des bnp-art und anp-art peptiden für das festsetzen der gefahren von herzgefäss- komplikationen als folge der volumenüberlastung ATE403157T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP04006080 2004-03-15

Publications (1)

Publication Number Publication Date
ATE403157T1 true ATE403157T1 (de) 2008-08-15

Family

ID=35005597

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05005356T ATE403157T1 (de) 2004-03-15 2005-03-11 Verwendung des bnp-art und anp-art peptiden für das festsetzen der gefahren von herzgefäss- komplikationen als folge der volumenüberlastung

Country Status (7)

Country Link
US (2) US20050239138A1 (de)
EP (1) EP1577673B1 (de)
JP (2) JP4343866B2 (de)
AT (1) ATE403157T1 (de)
CA (1) CA2500886C (de)
DE (1) DE602005008497D1 (de)
ES (1) ES2311895T3 (de)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1691200A1 (de) * 2005-02-14 2006-08-16 F. Hoffmann-La Roche Ag Verwendung des BNP-Art und ANP-Art Peptiden für das Festsetzen der Gefahren von Herzgefäß- Komplikationen als Folge der Volumenüberlastung
US7432107B2 (en) 2005-01-24 2008-10-07 Roche Diagnostics Operations, Inc. Cardiac hormones for assessing cardiovascular risk
PT1849009E (pt) 2005-01-24 2009-01-14 Hoffann La Roche Ag F Utilização de hormonas cardíacas para avaliar um risco cardiovascular em relação à administração de fármacos anti-inflamatórios
JP4654414B2 (ja) * 2005-12-01 2011-03-23 独立行政法人産業技術総合研究所 免疫化学的検出方法、及びその検出用試薬キット
WO2007079392A2 (en) * 2005-12-30 2007-07-12 The Trustees Of Columbia University In The City Of New York Real-time assays of neuro-humoral to assess cardiovascular stress
EP1816477A1 (de) * 2006-02-06 2007-08-08 F. Hoffmann-la Roche AG Verwendung von natriuretischen Peptiden und Plazentawachstumsfaktorwerten zur Risikostratifizierung von für Herzstresstests ausgewählten Personen
MX2009000914A (es) * 2006-08-04 2009-06-18 Hannover Med Hochschule Medios y metodos para evaluar el riesgo de intervenciones cardiacas basadas en el factor 15 de diferenciacion del crecimiento.
EP1970709B1 (de) * 2007-03-06 2013-07-10 Roche Diagnostics GmbH Verwendung von Peptiden vom Typ BNP zur Vorhersage des Dialysebedarfs
DE102007010834A1 (de) 2007-03-03 2008-09-04 Brahms Aktiengesellschaft Diagnose und Risikostratifizierung von Herzinsuffizienz für NYHA I Patienten
EP3656403B1 (de) 2007-08-17 2022-05-11 Purdue Research Foundation Verfahren zur herstellung von psma-bindende liganden-linker-konjugaten
WO2009047283A2 (en) * 2007-10-10 2009-04-16 Roche Diagnostics Gmbh Means and methods for monitoring myocardial infarction and its treatment
EP2103943A1 (de) 2008-03-20 2009-09-23 F. Hoffman-la Roche AG GDF-15 zur Beurteilung eines kardiovaskulären Risikos hinsichtlich Verabreichung von Entzündungshemmern
EP2133696A1 (de) 2008-06-10 2009-12-16 Eberhardt Spanuth Sehr geringe Konzentrationen von Troponin I oder T zur Beurteilung eines kardiovaskulären Risikos hinsichtlich der Verabreichung von Entzündungshemmern
US9951324B2 (en) 2010-02-25 2018-04-24 Purdue Research Foundation PSMA binding ligand-linker conjugates and methods for using
EP2769227B1 (de) 2011-10-17 2016-07-27 Roche Diagnostics GmbH Auf troponin und bnp basierende diagnose von risikopatienten und ursache eines schlaganfalls
CN102854321B (zh) * 2012-07-26 2015-09-02 博奥赛斯（天津）生物科技有限公司 N末端b型脑钠肽前体化学发光免疫定量检测试剂盒及其制备方法
RU2504780C1 (ru) * 2012-09-25 2014-01-20 ГОСУДАРСТВЕННОЕ БЮДЖЕТНОЕ ОБРАЗОВАТЕЛЬНОЕ УЧРЕЖДЕНИЕ ВЫСШЕГО ПРОФЕССИОНАЛЬНОГО ОБРАЗОВАНИЯ "НИЖЕГОРОДСКАЯ ГОСУДАРСТВЕННАЯ МЕДИЦИНСКАЯ АКАДЕМИЯ" МИНИСТЕРСТВА ЗДРАВООХРАНЕНИЯ И СОЦИАЛЬНОГО РАЗВИТИЯ РОССИЙСКОЙ ФЕДЕРАЦИИ (ГБОУ ВПО "НижГМА" МИНЗДРАВСОЦРАЗВИТИЯ РОССИИ) Способ оценки риска развития неблагоприятных сердечно-сосудистых событий у пациентов с заболеваниями миокарда, подвергшихся операции с искусственным кровообращением
MX2015006109A (es) 2012-11-15 2016-02-05 Endocyte Inc Conjugados para el tratamiento de enfermedades causadas por celulas que expresan psma.
GEP20237497B (en) 2013-10-18 2023-04-10 Deutsches Krebsforsch Labeled inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer
EP3777898B1 (de) 2013-11-14 2025-01-01 Endocyte, Inc. Verbindungen für positronenemissionstomografie
US10188759B2 (en) 2015-01-07 2019-01-29 Endocyte, Inc. Conjugates for imaging
WO2019204335A1 (en) 2018-04-17 2019-10-24 Endocyte, Inc. Methods of treating cancer
US12001939B2 (en) 2018-12-11 2024-06-04 Eko.Ai Pte. Ltd. Artificial intelligence (AI)-based guidance for an ultrasound device to improve capture of echo image views
US12322100B2 (en) 2018-12-11 2025-06-03 Eko.Ai Pte. Ltd. Automatic clinical workflow that recognizes and analyzes 2D and doppler modality echocardiogram images for automated cardiac measurements and grading of aortic stenosis severity
US12400762B2 (en) 2018-12-11 2025-08-26 Eko.Ai Pte. Ltd. Automatic clinical workflow that recognizes and analyzes 2D and doppler modality echocardiogram images for automated cardiac measurements and diagnosis of cardiac amyloidosis and hypertrophic cardiomyopathy
US11931207B2 (en) 2018-12-11 2024-03-19 Eko.Ai Pte. Ltd. Artificial intelligence (AI) recognition of echocardiogram images to enhance a mobile ultrasound device
US11446009B2 (en) 2018-12-11 2022-09-20 Eko.Ai Pte. Ltd. Clinical workflow to diagnose heart disease based on cardiac biomarker measurements and AI recognition of 2D and doppler modality echocardiogram images
EP3972627A4 (de) 2019-05-20 2023-06-21 Endocyte, Inc. Verfahren zur herstellung von psma-konjugaten
CN113571191A (zh) * 2021-08-31 2021-10-29 复旦大学附属中山医院 免疫检查点抑制剂相关mace发生风险的预测方法
WO2025019482A1 (en) * 2023-07-17 2025-01-23 Siemens Healthcare Diagnostics Inc. Methods, reagents, and kits for tuning an immunoassay signal

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5744101A (en) * 1989-06-07 1998-04-28 Affymax Technologies N.V. Photolabile nucleoside protecting groups
US6596476B1 (en) * 1989-12-22 2003-07-22 Abbott Laboratories Hepatitis C assay
US6190857B1 (en) * 1997-03-24 2001-02-20 Urocor, Inc. Diagnosis of disease state using MRNA profiles in peripheral leukocytes
US6622036B1 (en) * 2000-02-09 2003-09-16 Cns Response Method for classifying and treating physiologic brain imbalances using quantitative EEG
CA2349865C (en) * 1999-06-21 2014-08-19 Eli Lilly And Company Synergistic use of thiazolidinediones with glucagon-like peptide-1 and agonists thereof to treat metabolic instability associated with non-insulin dependent diabetes
AT407580B (de) * 1999-08-20 2001-04-25 Biomedica Gmbh Indikatorpeptid zur diagnose und/oder vorhersage von cardiovasculären und/oder endothelialen erkrankungen, antikörperzusammensetzung und immunoassay
US6689083B1 (en) * 2000-11-27 2004-02-10 Chf Solutions, Inc. Controller for ultrafiltration blood circuit which prevents hypotension by monitoring osmotic pressure in blood
FI20010019A7 (fi) * 2001-01-05 2002-07-06 Biohit Oyj Menetelmä atrofisen gastriitin diagnostisoimiseksi
US7632647B2 (en) * 2001-04-13 2009-12-15 Biosite Incorporated Use of B-type natriuretic peptide as a prognostic indicator in acute coronary syndromes
US6969472B2 (en) * 2001-04-19 2005-11-29 Lsi Logic Corporation Method of fabricating sub-micron hemispherical and hemicylidrical structures from non-spherically shaped templates
US7202089B2 (en) * 2001-09-14 2007-04-10 Alan Kleinfeld Early diagnosis of stroke
MXPA03004105A (es) * 2002-05-14 2004-10-15 Hoffmann La Roche Elaboracion de una prognosis en casos de enfermedad cardiaca usando una combinacion de marcadores.
US6960472B2 (en) * 2002-11-18 2005-11-01 Ottawa Heart Institute Research Corporation Monoclonal antibodies against N-Terminus proBNP
EP2318844A1 (de) * 2008-07-14 2011-05-11 Roche Diagnostics GmbH Multimarkerpanel zur diagnose, überwachung und auswahl der therapie für patienten mit herzinsuffizienz

Also Published As

Publication number Publication date
EP1577673A1 (de) 2005-09-21
JP2005274569A (ja) 2005-10-06
JP4343866B2 (ja) 2009-10-14
CA2500886C (en) 2010-08-10
US20110229907A1 (en) 2011-09-22
JP2009080130A (ja) 2009-04-16
ES2311895T3 (es) 2009-02-16
CA2500886A1 (en) 2005-09-15
JP4944868B2 (ja) 2012-06-06
EP1577673B1 (de) 2008-07-30
DE602005008497D1 (de) 2008-09-11
US20050239138A1 (en) 2005-10-27

Similar Documents

Publication Publication Date Title
ATE403157T1 (de) Verwendung des bnp-art und anp-art peptiden für das festsetzen der gefahren von herzgefäss- komplikationen als folge der volumenüberlastung
Reddy et al. Characterization of the obese phenotype of heart failure with preserved ejection fraction: a RELAX trial ancillary study
Miyatani et al. Pulse wave velocity for assessment of arterial stiffness among people with spinal cord injury: a pilot study
Tomiyama et al. Arterial stiffness and declines in individuals with normal renal function/early chronic kidney disease
Tomiyama et al. Influences of age and gender on results of noninvasive brachial–ankle pulse wave velocity measurement—a survey of 12 517 subjects
Wilkinson et al. Increased augmentation index and systolic stress in type 1 diabetes mellitus
DeBoer Obesity, systemic inflammation, and increased risk for cardiovascular disease and diabetes among adolescents: a need for screening tools to target interventions
Tatasciore et al. Awake blood pressure variability, inflammatory markers and target organ damage in newly diagnosed hypertension
Vogel Measurement of endothelial function by brachial artery flow-mediated vasodilation
Andersson et al. Relations of circulating GDF-15, soluble ST2, and troponin-I concentrations with vascular function in the community: The Framingham Heart Study
Moran et al. A comprehensive assessment of endothelial function in overweight women with and without polycystic ovary syndrome
ATE373827T1 (de) Kombination von markern für diabetes typ 1 und 2
Izumi et al. Effect of age at menopause on blood pressure in postmenopausal women
Kampus et al. The relationship between inflammation and arterial stiffness in patients with essential hypertension
de Berrazueta et al. Endothelial dysfunction, measured by reactive hyperaemia using strain-gauge plethysmography, is an independent predictor of adverse outcome in heart failure
DE602005001299D1 (de) Kombinationen von Markern zum Nachweis von typ 1 und 2 Diabetes
JP2011516874A (ja) 最大酸素消費量低下の予測のためのプロ−エンドセリン−１
Nalcacioglu et al. Is N-terminal pro-brain natriuretic peptide a reliable marker for body fluid status in children with chronic kidney disease?
O'Donnell et al. Relationships between vascular resistance and energy deficiency, nutritional status and oxidative stress in oestrogen deficient physically active women
Bilinska et al. Influence of dynamic training on hemodynamic, neurohormonal responses to static exercise and on inflammatory markers in patients after coronary artery bypass grafting
Mandalenakis et al. Atrial natriuretic peptide as a predictor of atrial fibrillation in a male population study. The Study of Men Born in 1913 and 1923
Egbe et al. Determinants and prognostic implications of left atrial reverse remodelling after coarctation of aorta repair in adults
Tomiyama et al. Elevated C-reactive protein: a common marker for atherosclerotic cardiovascular risk and subclinical stages of pulmonary dysfunction and osteopenia in a healthy population
New et al. Free Radical–Mediated Lipid Peroxidation and Systemic Nitric Oxide Bioavailability: Implications for Postexercise Hemodynamics
Kurihara et al. Excessive alcohol intake increases the risk of arterial stiffening in men with normal blood pressure

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties